|
A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy. Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy. conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy. Clinical research trials and A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy. health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.. A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy. Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy. clinical trial. Subjects frequently get the best healthcare possible for their A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy. condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.  A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.
A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.
For Condition: Breast Cancer
Status: Recruiting
Sponsor(s): Abbott Laboratories ,
Synopsis: The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with breast cancer after having had taxol or taxotere. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: - Stage IIIB or IV breast cancer. - Recurrent tumor after or while on taxane therapy (taxol or taxotere). - Not pregnant or breast feeding. - Able to tolerate normal activites of daily living. - No anti-tumor therapy (including hormonal therapy or Herceptin) within 4 weeks of the start of ABT-751 administration. - Adequate bone marrow, kidney and liver function.
Total Enrollment:
Location and Contact Information:
Indiana University Cancer Center Section of of Hemtology/Oncology Indiana Cancer Pavilion *Recruiting*
Indianapolis, Indiana, 46202
United States
Recruiting Darlene Washington 317-278-3730
Oncology & Hemotology Associates of Kansas City, PA *Recruiting*
Kansas City, Missouri, 64111
United States
Recruiting Vickie Thomas 913-514-4641
Northwestern University Medical School Division of Hemtology/Oncology *Recruiting*
Chicago, Illinois, 60611
United States
Recruiting Sarah Shin 312-695-1382
Northern Indiana Cancer Research Consortium *Recruiting*
South Bend, Indiana,
United States
Recruiting Susan Haithcox 574-284-7977
Oncology-Hematology Group of South Florida *Recruiting*
Miami, Florida, 33176
United States
Recruiting Julie Reed 305-595-2141
Texas Oncology *Recruiting*
Dallas, Texas,
United States
Recruiting Jeremy Day 972-566-4392
Georgia Cancer Specialists *Recruiting*
Atlanta, Georgia,
United States
Recruiting Christopher Moore 770-496-9427
Clinical Research Network, Inc. *Recruiting*
Plantation, Florida, 33324
United States
Recruiting Cynthia Frankel 954-476-0342
Additional Information:
Study ID Numbers: M02-447;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00063102
Other Breast Cancer Studies:
1. Docetaxel and Flavopiridol to Treat Breast Cancer
2. Phase II trial of oral study drug in patients with advanced metastatic breast cancer who have experienced failure of an anthracycline, a taxane, and capecitabine
3. Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced or Metastatic Breast Cancer
4. Vaccination Against Melanoma and Other Cancers
5. Efficacy and safety study of letrozole plus ZARNESTRA or placebo in the treatment of advanced breast cancer.
Related Studies:
Other Breast Cancer Clinical Trials
Other Georgia Clinical Trials
Other Atlanta Clinical Trials
A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.
|
|
|
|
|
|
|
|
